APC Anti-Neuropilin 1 antibody [EPR3113],Abcam,AB310882

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

IHC-P, Target Binding Affinity, Antibody Labelling, Flow Cyt (Intra), ICC/IF

Conjugate

APC

Platform ID

BAB022799609

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAPC Anti-Neuropilin 1 antibody [EPR3113]
Cat. No.AB310882
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ConjugationAPC
ApplicationIHC-P, Target Binding Affinity, Antibody Labelling, Flow Cyt (Intra), ICC/IF
ClonalityMonoclonal
Clone NumberEPR3113
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Cell-surface receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. Mediates the chemorepulsant activity of semaphorins (PubMed : 10688880, PubMed : 9288753, PubMed : 9529250). Recognizes a C-end rule (CendR) motif R/KXXR/K on its ligands which causes cellular internalization and vascular leakage (PubMed : 19805273). It binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF165 isoform of VEGFA and VEGFB (PubMed : 10688880, PubMed : 19805273, PubMed : 9288753, PubMed : 9529250). Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulates VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Regulates mitochondrial iron transport via interaction with ABCB8/MITOSUR (PubMed : 30623799).. (Microbial infection) Acts as a host factor for human coronavirus SARS-CoV-2 infection. Recognizes and binds to CendR motif RRAR on SARS-CoV-2 spike protein S1 which enhances SARS-CoV-2 infection.. Isoform 2. Binds VEGF-165 and may inhibit its binding to cells (PubMed : 10748121, PubMed : 26503042). May induce apoptosis by sequestering VEGF-165 (PubMed : 10748121). May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity. See full target information NRP1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.